
Pharmaceuticals & Chemicals · BSE
Incorporated in 2008, Sudarshan Pharma Industries Limited (SPIL) is a Mumbai-based company engaged in contract manufacturing, import, export, and supply of specialty chemicals, Active Pharmaceutical Ingredients (APIs), and intermediates. The company sources and supplies generic formulations by outsourcing manufacturing facilities from domestic and international suppliers based on client requirements. Its products find applications across industries such as pharmaceuticals, paints, food, and adhesives. SPIL also supplies medicines and pharma formulations to hospitals, NGOs, government bodies, and healthcare institutions under its own brand, offering around 50 formulations in tablets, capsules, ointments, and injectables. With a strong sales and distribution network across five states, the company markets its products ethically in both Indian and international markets, while also offering formulation development, quality control, and customized pharma solutions.
Price Band
₹71 – ₹73
Issue Size
₹50.10 Cr
Lot Size
1600 shares
GMP
Est. Listing
₹73
at current GMP
Subscribed
1.06x
overall
Open
9 Mar 2023
Close
14 Mar 2023
Allotment
18 Mar 2023
Refund
19 Mar 2023
Demat Credit
20 Mar 2023
Listing
20 Mar 2023
Designated Registrar: Kfin Technologies Limited
Allotment Date
18 Mar 2023
Basis finalization
Refunds Initiate
19 Mar 2023
Mandate release
Demat Credit
20 Mar 2023
Shares in demat
Listing Debut
20 Mar 2023
Trading begins
Sudarshan Pharma Industries Limited is bringing an initial public offering (IPO) in the Pharmaceuticals & Chemicals sector with an aggregate issue size of ₹50.1 Crores. The shares are offered at a price band of ₹71 to ₹73 per equity share on BSE. Currently, traders and retail applicants are calculating expected listing gains and break-even points based on unofficial grey market quotations.
Prospective investors can apply in the retail quota with a minimum of 1 lot comprising 1600 shares (approx. ₹1,16,800 minimum investment). High net-worth individuals (HNI/NII) can bid in the sHNI (₹2 Lakh to ₹10 Lakh) or bHNI (above ₹10 Lakh) categories for enhanced quota allocation.
Allotment reconciliation will be managed by Kfin Technologies Limited. Eligible allottees will receive credit of equity shares into their Demat accounts by 2023-03-20, while un-allotted funds or UPI block mandates will be released on 2023-03-19.
Allotment records are updated in batches. If the status is not yet available, please wait a few hours until the basis of allotment is fully finalized.
Since funds are blocked under ASBA/UPI, the bank will automatically release the blocked hold on your funds upon receipt of revocation instructions from the sponsor bank.